Viking Therapeutics, Inc. (0VQA.L)
USD 39.07
(-17.95%)
USD 39.07
(-17.95%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -292 Thousand USD | -0.34% |
| 2022 | -291 Thousand USD | 1.69% |
| 2021 | -296 Thousand USD | -6.86% |
| 2020 | -277 Thousand USD | -6.54% |
| 2019 | -260 Thousand USD | 0.0% |
| 2018 | - USD | 0.0% |
| 2017 | - USD | 0.0% |
| 2016 | - USD | 0.0% |
| 2015 | - USD | 0.0% |
| 2014 | - USD | 0.0% |
| 2013 | - USD | 0.0% |
| 2012 | - USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | -74 Thousand USD | -120.44% |
| 2024 Q2 | -75 Thousand USD | -1.35% |
| 2024 Q3 | -87 Thousand USD | -16.0% |
| 2023 Q1 | -72 Thousand USD | 0.0% |
| 2023 Q3 | -73 Thousand USD | 0.0% |
| 2023 Q2 | -73 Thousand USD | -1.39% |
| 2023 Q4 | 362 Thousand USD | 595.89% |
| 2023 FY | -292 Thousand USD | -0.34% |
| 2022 Q4 | -72 Thousand USD | 49.3% |
| 2022 Q2 | - USD | 100.0% |
| 2022 Q1 | -77 Thousand USD | -1.32% |
| 2022 FY | -291 Thousand USD | 1.69% |
| 2022 Q3 | -142 Thousand USD | 0.0% |
| 2021 FY | -296 Thousand USD | -6.86% |
| 2021 Q3 | -75 Thousand USD | -2.74% |
| 2021 Q1 | -72 Thousand USD | 0.0% |
| 2021 Q2 | -73 Thousand USD | -1.39% |
| 2021 Q4 | -76 Thousand USD | -1.33% |
| 2020 FY | -277 Thousand USD | -6.54% |
| 2020 Q4 | - USD | 0.0% |
| 2020 Q3 | - USD | 0.0% |
| 2020 Q2 | - USD | 0.0% |
| 2020 Q1 | - USD | 0.0% |
| 2019 FY | -260 Thousand USD | 0.0% |
| 2019 Q4 | - USD | 0.0% |
| 2019 Q3 | - USD | 0.0% |
| 2019 Q2 | - USD | 0.0% |
| 2019 Q1 | - USD | 0.0% |
| 2018 Q2 | - USD | 0.0% |
| 2018 FY | - USD | 0.0% |
| 2018 Q4 | - USD | 0.0% |
| 2018 Q3 | - USD | 0.0% |
| 2018 Q1 | - USD | 0.0% |
| 2017 Q4 | - USD | 0.0% |
| 2017 Q3 | - USD | 0.0% |
| 2017 Q2 | - USD | 0.0% |
| 2017 Q1 | - USD | 0.0% |
| 2017 FY | - USD | 0.0% |
| 2016 Q3 | - USD | 0.0% |
| 2016 FY | - USD | 0.0% |
| 2016 Q1 | - USD | 0.0% |
| 2016 Q2 | - USD | 0.0% |
| 2016 Q4 | - USD | 0.0% |
| 2015 Q1 | - USD | 0.0% |
| 2015 Q2 | - USD | 0.0% |
| 2015 Q4 | - USD | 0.0% |
| 2015 Q3 | - USD | 0.0% |
| 2015 FY | - USD | 0.0% |
| 2014 Q1 | - USD | 0.0% |
| 2014 Q2 | - USD | 0.0% |
| 2014 Q3 | - USD | 0.0% |
| 2014 Q4 | - USD | 0.0% |
| 2014 FY | - USD | 0.0% |
| 2013 Q1 | - USD | 0.0% |
| 2013 Q3 | - USD | 0.0% |
| 2013 Q4 | - USD | 0.0% |
| 2013 Q2 | - USD | 0.0% |
| 2013 FY | - USD | 0.0% |
| 2012 Q4 | - USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Editas Medicine, Inc. | -99.52 Million USD | 99.707% |
| Dynavax Technologies Corporation | 182.11 Million USD | 100.16% |
| Supernus Pharmaceuticals, Inc. | 523.74 Million USD | 100.056% |
| Perrigo Company plc | 1.68 Billion USD | 100.017% |
| Illumina, Inc. | 2.74 Billion USD | 100.011% |
| Thermo Fisher Scientific Inc. | 15.22 Billion USD | 100.002% |
| Iovance Biotherapeutics, Inc. | -9.56 Million USD | 96.948% |
| Walgreens Boots Alliance, Inc. | 26.52 Billion USD | 100.001% |
| IQVIA Holdings Inc. | 5.23 Billion USD | 100.006% |
| Heron Therapeutics, Inc. | 10.04 Million USD | 102.908% |
| Regeneron Pharmaceuticals, Inc. | 11.3 Billion USD | 100.003% |
| Unity Biotechnology, Inc. | -19.69 Million USD | 98.518% |
| Waters Corporation | 1.76 Billion USD | 100.017% |
| Biogen Inc. | 7.3 Billion USD | 100.004% |
| Sangamo Therapeutics, Inc. | -45.32 Million USD | 99.356% |
| Evolus, Inc. | 140.52 Million USD | 100.208% |
| Adicet Bio, Inc. | -6.09 Million USD | 95.212% |
| Cara Therapeutics, Inc. | 14.79 Million USD | 101.974% |
| bluebird bio, Inc. | -4.03 Million USD | 92.754% |
| Esperion Therapeutics, Inc. | 73.06 Million USD | 100.4% |
| FibroGen, Inc. | 128.9 Million USD | 100.227% |
| Agilent Technologies, Inc. | 3.46 Billion USD | 100.008% |
| Corbus Pharmaceuticals Holdings, Inc. | -31.16 Million USD | 99.063% |
| Homology Medicines, Inc. | -7.22 Million USD | 95.961% |
| Geron Corporation | -123.5 Million USD | 99.764% |
| Alnylam Pharmaceuticals, Inc. | 1.51 Billion USD | 100.019% |
| Amicus Therapeutics, Inc. | 362.03 Million USD | 100.081% |
| Myriad Genetics, Inc. | 476.4 Million USD | 100.061% |
| Intellia Therapeutics, Inc. | -398.79 Million USD | 99.927% |
| Zoetis Inc. | 5.83 Billion USD | 100.005% |
| Abeona Therapeutics Inc. | 302 Thousand USD | 196.689% |
| Mettler-Toledo International Inc. | 2.16 Billion USD | 100.013% |
| BioMarin Pharmaceutical Inc. | 1.9 Billion USD | 100.015% |
| Vertex Pharmaceuticals Incorporated | 8.6 Billion USD | 100.003% |
| Kala Pharmaceuticals, Inc. | -303 Thousand USD | 3.63% |
| Ionis Pharmaceuticals, Inc. | 778.51 Million USD | 100.038% |
| Atara Biotherapeutics, Inc. | -313 Thousand USD | 6.709% |
| Verastem, Inc. | -62 Thousand USD | -370.968% |
| Nektar Therapeutics | 53.47 Million USD | 100.546% |
| Axsome Therapeutics, Inc. | 244.53 Million USD | 100.119% |
| Aclaris Therapeutics, Inc. | -85.21 Million USD | 99.657% |
| Sarepta Therapeutics, Inc. | 1.09 Billion USD | 100.027% |
| OPKO Health, Inc. | 318.12 Million USD | 100.092% |
| Exelixis, Inc. | 1.75 Billion USD | 100.017% |
| Neurocrine Biosciences, Inc. | 1.84 Billion USD | 100.016% |
| Corcept Therapeutics Incorporated | 475.89 Million USD | 100.061% |
| Anavex Life Sciences Corp. | - USD | Infinity% |
| uniQure N.V. | 2.21 Million USD | 113.183% |
| Imunon, Inc. | -720 Thousand USD | 59.445% |
| Blueprint Medicines Corporation | 236.58 Million USD | 100.123% |
| Insmed Incorporated | 239.63 Million USD | 100.122% |
| Halozyme Therapeutics, Inc. | 636.89 Million USD | 100.046% |
| Agios Pharmaceuticals, Inc. | 17.31 Million USD | 101.686% |
| TG Therapeutics, Inc. | 219.1 Million USD | 100.133% |
| Incyte Corporation | 3.44 Billion USD | 100.008% |
| Emergent BioSolutions Inc. | 343.9 Million USD | 100.085% |